Abstract
Background and aims The IBD-Character consortium has recruited large internationally based inception cohorts of treatment-naïve inflammatory bowel disease (IBD) patients, providing a unique resource to derive a simple transcriptome signature in the field of prognostication.
Methods The discovery cohort (n=160) was recruited in Norway, Sweden and Spain. The replication inception cohort from the United Kingdom (n=97) was followed-up for a mean (±SD) of 350±228 days. Treatment escalation was formally defined as the need for a biologic agent, ciclosporin and/or surgery, instituted for disease flare after initial remission, or colectomy during the index admission for ulcerative colitis. Whole blood RNA was subject to paired-end sequencing. In the discovery cohort a simple procedure was applied, which exploited differences of transcript ratios. The ten top performing ratios were tested using Cox regression models in the validation cohort.
Results Newly diagnosed IBD patients with high CACNA1E/LRRC42 expression ratio had an increased risk of treatment intensification (validation cohort: HR=19.3, 95%CI 2.6–143.9, p=0.000005; AUC 0.76, 95%CI 0.66–0.86). In 51 patients with CRP < 3.5 mg/L, CACNA1E/LRRC42 still predicted escalation (HR=10.4; 95%CI 1.2-86.5, p=0.007). The second best performing transcript ratio was CACNA1E/CEACAM21 yielding a HR of 10.9 (95%CI 2.5-46.7, p=0.00002) and an AUC of 0.76 (95%CI 0.65-0.86) in the validation cohort.
Conclusion Transcriptomic profiling of an IBD inception cohort identified gene expression ratios CACNA1E/LRRC42 and CACNA1E/CEACAM21 as prognostic biomarkers. These were validated in a replication cohort as strongly associated with short- and long-term risk of treatment intensification and may provide valuable information in clinical decision-making.
Competing Interest Statement
JKN reports personal fees from Norsa Pharma, a grant from Biocodex Microbiota Foundation, and non-financial support from Nutricia outside the submitted work. ATA reports no conflict of interest. RK has served as a speaker for Ferring and has received support for research from IBD-Character (EU FP7 2858546). JH has received personal fees as speaker, consultant and/or advisory board member for AbbVie, Aqilion AB, Celgene, Celltrion, Dr. Falk Pharma and the Falk Foundation, Ferring, Hospira, Janssen, MEDA, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz/Novartis, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD, and Takeda, outside the submitted work. JS has served as a speaker, a consultant and an advisory board member for MSD, Ferring Abbvie and Shire, consultant with Takeda, received speaking fees from MSD, travel support from Shire, and has received research funding from Abbvie, Wellcome, CSO, MRC, and the EC grant IBDBIOM.
Funding Statement
EU FP7 grant IBD-Character (2858546).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the NHS Lothian Research Ethics Committee. All the patients provided informed written consent for their participation in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
IBD Character Consortium: Erik Andersson, Ian D Arnott, MD, Monica Bayes, PhD, Daniel Bergemalm, PhD, Ferdinando Bonfiglio, PhD, Ray K Boyapati, MD, Adam Carstens, MD, Christina Casén, MSc, Ewa Ciemniejewska, MSc, Mauro D’Amato, PhD, Fredrik A Dahl, PhD, Trond Espen Detlie, MD, Hazel E Drummond, BSc, Gunn S Ekeland, MSc, Daniel Ekman, MSc, Anna B Frengen, PhD, Fernando Gomollón, PhD, Mats Gullberg, PhD, Ivo G Gut, PhD, Marta Gut, PhD, Simon C Heath, PhD, Fredrik Hjelm, PhD, Henrik Hjortswang, MD, PhD, Gwo-Tzer Ho, PhD, Jørgen Jahnsen, PhD, Daisy Jonkers, PhD, Åsa V. Keita, PhD, Nicholas A Kennedy, MBBS, PhD, FRACP, Charles W Lees, PhD, Torbjørn Lindahl, MSc, Jonas C Lindstrøm, PhD, Mårten Lindqvist, PhD, Angelika Merkel, PhD, Eddie Modig, Bsc, Aina EF Moen, PhD, Hilde Nilsen, PhD, Elaine R Nimmo, PhD, Colin L Noble, MD, Niklas Nordberg, PhD, Kate R O’Leary, MSc, Anette Ocklind, PhD, Christine Olbjørn, MD, Erik Pettersson, PhD, Marieke Pierik, MD, PhD, Dominique Poncelet, PhD, Dirk Repsilber, PhD, Petr Ricanek, PhD, Céline Sabatel, PhD, Renaud Schoemans, PhD, Alan G Shand, MD, Johan D. Söderholm, MD, PhD, Janne Sølvernes, MS, Mikael Sundell, BSc, Tone M Tannæs, PhD, Leif Törkvist, MD, PhD, Morten H Vatn, PhD, Simen Vatn, PhD, Anne-Clémence Veillard, PhD, Nicholas T Ventham, MRCS(Eng) PhD, MBBS, David C Wilson, MD, MRCPCH, Panpan You, MS.
Funding: EU FP7 grant IBD-Character (2858546).
Data Availability
The data supporting the findings of this study will be available from the authors upon reasonable request.
